The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The extraordinary solution with the exclusive therapy of Glucox Biotech is that it effectively increase glucose uptake in muscle and dramatically improves insulin sensitivity and thus remove the probable cause of the blunted insulin response.
| Website | http://www.glucoxbiotech.com |
| Revenue | $5 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2003 |
| Address | 7 Wollmar Yxkullsgatan, Stockholm, Stockholm 11850, SE |
| Phone | +46 73 690 30 10 |
| Technologies |
JavaScript
,
HTML
,
PHP
+5 more
(view full list)
|
| Industry | Pharmaceuticals, Business Services General, Business Services |
| Keywords | Type 2 Diabetes Treatment, Therapeutic Drug Development, Diabetes Management, Diabetes Medication, Clinical Stage Drug, Innovative Diabetes Solutions, Metabolic Disease Treatment, Glucose Metabolism, Endocrine Disorders, Pharmaceutical Research, Drug Development Pipeline, Clinical Trials |
| Competitors | Novo Nordisk, AstraZeneca, Genentech, Amgen, Insulet Corporation, DiaSorin, Nordic Bioscience A/S, Lilly India, ZyVersa Therapeutics Inc., Sernova Corp. +39 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies |
Looking for a particular Glucox Biotech AB employee's phone or email?
Glucox Biotech AB Questions
The Glucox Biotech AB annual revenue was $5 million in 2026.
Glucox Biotech AB is based in Stockholm, Stockholm.
The NAICS codes for Glucox Biotech AB are [541713, 54, 541, 5417, 54171].
The SIC codes for Glucox Biotech AB are [87, 873].
Related Companies
